Compare Abeona Therapeutics Inc (ABEO) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Target Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Target Corporation trades at $133.4 (market cap $57.93B). The key difference: Target Corporation is far larger — about 155.2× Abeona Therapeutics Inc's market cap, and Target Corporation pays a 3.64% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TGT | |
|---|---|---|
Market Cap | $373.32M | $57.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $141.19 |
52-Week Low | $4.17 | $83.68 |
Enterprise Value | $228.22M | $73.23B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Target trades at $127.55, down 2.04% today, with technical indicators showing bearish momentum. The stock maintains solid fundamentals with a P/E of 16.66 and net income margin of 3.24%, supported by three consecutive quarterly EPS beats. Recent news highlights Target's marketplace expansion and consumer resilience focus amid retail sector volatility.
The outlook remains balanced with a consensus price target of $137 offering 7.4% upside potential, though bearish technical signals and competitive pressures pose risks. Strong cash flow generation and dividend payments provide shareholder stability while execution on growth initiatives will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
